Activation of SMN in human fibroblast cells obtained from type 1 SMA patients assessed as increase in SMN protein level by quantitative Western blot method
Activation of SMN expressed in HEK293 cells assessed as rate of induction by SMN2-promotor driven luciferase reporter gene assay relative to basal level
Activation of SMN expressed in HEK293 cells assessed as concentration required to reach 50% of maximum luciferase signal by SMN2-promotor driven luciferase reporter gene assay
Activation of SMN in human fibroblast cells obtained from type 1 SMA patients assessed as protein punctuate bodies per 100 nuclei at 37 nM relative to control
Activation of SMN in human fibroblast cells obtained from type 1 SMA patients assessed as protein punctuate bodies per 100 nuclei at 37 to 1000 nM relative to control
PUBCHEM_BIOASSAY: Confirmation Concentration-Response Assay for Enhancers of SMN2 Splice Variant Expression for Further Probe SAR. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1474]
PUBCHEM_BIOASSAY: Counterscreen Assay for Enhancers of SMN2 Splice Variant Expression: Modulation of SMN1 Expression for Further Probe SAR. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID1474]
Stabilization of human SMN protein expressed in HEK293 cells expressing SMN2 promoter after 24 hrs by luciferase reporter gene assay relative to control
Stabilization of SMN protein in 3813T fibroblasts derived from human SMA patient assessed as increase in SMN protein level after 48 hrs by SDS-PAGE and immunoblot
Stabilization of SMN protein in 3813T fibroblasts derived from human SMA patient assessed as increase in SMN protein level at 2 uM after 48 hrs by by SDS-PAGE and immunoblot
Stabilization of SMN protein in 3814T fibroblasts derived from human SMA patient assessed as increase in SMN protein level after 48 hrs by SDS-PAGE and immunoblot